{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-214241","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.610609+00:00","generated_at":"2026-05-31T06:17:35.328243+00:00","sec_items":["5.07","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nuvation Bio shareholders approve 85M share conversion; CEO Hung named Board Chair","bullets":["Shareholders approved conversion of Series A Preferred into up to 85,120,200 Class A shares; conversion completed Sept 4, resulting in 333.8M Class A shares outstanding.","CEO David Hung appointed Chair of the Board; Robert Bazemore appointed Lead Independent Director.","Committee chairs set: Falberg (Audit), Vernon (Compensation), Bazemore (Nominating/Governance).","All five proposals passed: directors elected, KPMG ratified, executive compensation approved, conversion approved, adjournment approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-214241","json":"https://secwatch.observer/filing/0001193125-24-214241.json","markdown":"https://secwatch.observer/filing/0001193125-24-214241.md","text":"https://secwatch.observer/filing/0001193125-24-214241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524214241/0001193125-24-214241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524214241/d888247d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:17:35.328243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}